Premium
Retrospective study of the adverse events of the treatment for an acute attack of neuromyelitis optica spectrum disorder
Author(s) -
VeerachitOlarn Titinan,
Siritho Sasitorn,
Prayoonwiwat Naraporn
Publication year - 2020
Publication title -
therapeutic apheresis and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 53
eISSN - 1744-9987
pISSN - 1744-9979
DOI - 10.1111/1744-9987.13456
Subject(s) - medicine , adverse effect , neuromyelitis optica , spectrum disorder , methylprednisolone , pediatrics , anesthesia , retrospective cohort study , multiple sclerosis , immunology , psychiatry
Intravenous methylprednisolone (IVMP) is an initially recommended therapy for an acute attack of neuromyelitis optica spectrum disorder (NMOSD). For those who do not respond to steroid treatment, plasma exchange (PLEX) is generally added‐on. We evaluated adverse events of an acute treatment in NMOSD patients in a university‐based hospital during January 2009 and December 2017. Ninety‐seven patients with 177 attacks were collected. The therapy included IVMP alone (123 events, 62.4%), IVMP followed by PLEX (46 events, 23.4%) and, PLEX alone (8 events, 4.5%). Adverse events occurred in 36.7% of the IVMP group and 61.1% of the PLEX group. The most common adverse event was hyperglycemia (43.5%) followed by infection (29%) in the former and hypocalcemia (63.6%) followed by hypofibrinogen (42.4%), hypotension (30.3%), and infection (21.2%) in the latter. One severe adverse event was documented in the IVMP group and 13 events in the PLEX groups, nevertheless, all were manageable.